US defense secretary Pete Hegseth has announced a new health initiative aimed at screening service members for testosterone deficiency. In a video posted to X, Hegseth stated that the program is designed to ensure troops maintain the “right testosterone levels” to perform at their peak. He emphasized that the modern battlefield is “brutal and unrelenting,” requiring maximum psychological and mental readiness. By identifying these health markers early, Hegseth argued the department can keep service members on the “leading edge of lethality.”
Under the new plan, “warfighters” aged 30 and older will undergo annual testosterone testing as part of their routine health assessments. Participation for those under the age of 30 will be optional, allowing them to opt in if they choose. Hegseth clarified that any resulting treatment, such as testosterone replacement therapy, is entirely voluntary and intended to “restore and optimize” natural capabilities. He framed the program as part of a broader commitment to providing “elite medical care” to ensure personnel remain strong and resilient throughout their lives and careers.
The announcement follows a growing trend of political focus on testosterone levels within the current administration. Health secretary Robert F. Kennedy Jr., 72, has previously promoted the use of testosterone injections as part of his own anti-aging regimen and has alleged, without providing evidence, that American teenagers currently possess only half the testosterone levels of a 65-year-old man. The topic has also been popularized by various alternative media figures and influencers who advocate for hormone treatments as a means to combat a perceived crisis of masculinity. Research published in the journal Social Science & Medicine, however, suggests that young men are being aggressively targeted by wellness companies for hormone treatments that are often medically unwarranted for their age group.
The American Urological Association issued a statement in response, acknowledging the administration's recognition of the importance of screening. However, the association cautioned that a diagnosis of testosterone deficiency should never be based on a single blood test. Instead, they noted that such tests could serve as a “baseline value” for individuals requiring further evaluation, emphasizing that a formal diagnosis should be based on a combination of symptoms and two separate tests. Notably, Hegseth’s announcement did not address how the policy would apply to the more than 231,000 women serving as active duty members in the US military.
